evogliptin

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2014-2018
02420142018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
The objective of this study was to determine the absorption, excretion, and metabolism of a novel, oral antihyperglycemic drug… (More)
Is this relevant?
2017
2017
Evogliptin is a novel potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor. The aim of the present study was to evaluate… (More)
Is this relevant?
2017
2017
Evogliptin ((R)-4-((R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl)-3-(tert-butoxymethyl) piperazine-2-one)) is a highly potent… (More)
Is this relevant?
2017
2017
OBJECTIVES The aim of this study was to compare the pharmacokinetic (PK) characteristics of evogliptin and metformin following… (More)
Is this relevant?
Review
2016
Review
2016
INTRODUCTION Dipeptidyl peptidase-4 (DPP-4) inhibitors are novel, potent oral antihyperglycemic agents that reduce degradation of… (More)
  • table 1
  • table 4
  • figure 1
  • figure 2
Is this relevant?
2016
2016
Although multiple dipeptidyl peptidase 4 (DPP4) inhibitors have shown glucose-lowering effects by preserving pancreatic cells in… (More)
Is this relevant?
2015
2015
Evogliptin (Suganon) is an orally bioavailable, selective dipeptidyl peptidase-4 (DPP-4; CD26 antigen) inhibitor being developed… (More)
Is this relevant?
2015
2015
Evogliptin ((R)-4-((R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl)-3-(tert-butoxymethyl)-piperazin-2-one), is a new dipeptidyl… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2015
2015
Although dipeptidyl peptidase 4 (DPP4) is an adipokine known to positively correlate with adiposity, the effects of… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2014
2014
PURPOSE Evogliptin (DA-1229) is a novel, potent, and selective dipeptidyl peptidase IV (DPP-IV) inhibitor in clinical development… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?